Selective mGluR1 Antagonists for Chronic Pain
Solution Overview
Problem
Current therapies for chronic pain, particularly those targeting glutamate receptors, often have significant side effects due to their impact on normal excitatory synaptic transmission, necessitating the development of selective metabotropic glutamate receptor 1 (mGluR1) antagonists that can effectively manage pain without these adverse effects.
Innovation Solution
Development of tricyclic compounds that act as selective mGluR1 antagonists, which can be used in pharmaceutical compositions to treat pain, migraine, anxiety, urinary incontinence, and neurodegenerative diseases like Alzheimer's, by inhibiting mGluR1-mediated processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor antagonists are used to treat chronic pain, then pain relief is achieved, but significant side effects occur including psychosis, hyperactivity, fatigue, dizziness, amnesia and neuronal toxicity
Solution Approach 1:
The invention segments the glutamate receptor targeting approach by specifically selecting mGluR1 as the target subtype rather than using broad-spectrum NMDA antagonists. This segmentation allows selective modulation of pain pathways while preserving normal excitatory transmission in other brain regions, thereby achieving pain relief without the severe side effects of NMDA antagonists
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular structures (tricyclic, tetracyclic, and bicyclic frameworks with particular substituent patterns) that confer selective affinity for mGluR1 over other glutamate receptors. This molecular-level local quality ensures the drug acts precisely on the intended target, producing therapeutic effects without affecting other neural pathways
2Object-affected harmful factors
If selective mGluR1 antagonists are developed to reduce side effects, then normal excitatory synaptic transmission is preserved, but the complexity of achieving selectivity increases
Solution Approach 1:
The invention employs parameter changes by systematically varying molecular parameters such as ring structure type (tricyclic, tetracyclic, bicyclic), substituent positions, and functional group compositions to optimize both selectivity and potency. By adjusting these chemical parameters, the patent achieves high mGluR1 selectivity while maintaining manageable molecular complexity
Solution Approach 2:
The patent utilizes composite molecular structures combining multiple structural elements (core rings, bridging groups, substituent moieties) into integrated compounds. These composite structures leverage synergistic interactions between different molecular components to achieve selective mGluR1 binding, effectively managing complexity through structured composition rather than simple molecular weight increases
3Object-affected harmful factors
If mGluR1 antagonists are used to modify abnormal pain transmission, then therapeutic benefits are achieved with reduced side effects, but the scope of application to multiple diseases requires broad pharmacological activity
Solution Approach 1:
The invention achieves universality by demonstrating that mGluR1 antagonists can treat multiple disease conditions (chronic pain, migraine, anxiety, urinary incontinence, neurodegenerative diseases) through a single mechanism of action. The same compound class exhibits therapeutic effects across diverse indications, leveraging the central role of mGluR1 in various pathological processes
Data Source
AI summary
In its many embodiments, the present invention provides tricyclic compounds of formula (I) (wherein J1 - J4, X, and R1- R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.